Mayo Clinic
This study explores the potential value of a new blood test approach to detect measurable residual disease or early recurrence/progression in patients with cholangiocarcinoma.
PRIMARY OBJECTIVES: I. To estimate the association of PUMA levels from peripheral blood with disease progression (radiographically or clinically) in patients that are candidates for curative surgical intervention of cholangiocarcinoma. Ia. Pre- and post-neoadjuvant-treatment PUMA levels will be associated with treatment response to neoadjuvant therapy (short term progression). Ib. Pre-surgical and post-surgical PUMA levels will be associated with progression free survival. II. To estimate the association of PUMA levels from peripheral blood with postoperative survival in patients treated f…
Inclusion Criteria: * Patient has a suspected or clinical diagnosis of cholangiocarcinoma and under evaluation for surgical intervention with intent to cure * Age ≥ 18 years Exclusion Criteria: * Patient has metastatic disease involving other organs (excluding lymph node) * Patent has known primary cancer outside of the bile ducts within the last 3 years prior to blood collection (not including basal cell or squamous cell skin cancers, indolent cancer not requiring treatment within 3 years i.e. kidney, prostate or thyroid being observed) * Patient has had surgery to remove current target pa…
Non-Interventional Study
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.